{"pmid":32333915,"title":"Association of Respiratory Allergy, Asthma and Expression of the SARS-CoV-2 Receptor, ACE2.","text":["Association of Respiratory Allergy, Asthma and Expression of the SARS-CoV-2 Receptor, ACE2.","Underlying respiratory allergy and experimental allergen exposure reduce the expression of the SARS-CoV-2 receptor, ACE2, which could lead to reduced COVID-19 susceptibility.","J Allergy Clin Immunol","Jackson, Daniel J","Busse, William W","Bacharier, Leonard B","Kattan, Meyer","O'Connor, George T","Wood, Robert A","Visness, Cynthia M","Durham, Stephen R","Larson, David","Esnault, Stephane","Ober, Carole","Gergen, Peter J","Becker, Patrice","Togias, Alkis","Gern, James E","Altman, Mathew C","32333915"],"abstract":["Underlying respiratory allergy and experimental allergen exposure reduce the expression of the SARS-CoV-2 receptor, ACE2, which could lead to reduced COVID-19 susceptibility."],"journal":"J Allergy Clin Immunol","authors":["Jackson, Daniel J","Busse, William W","Bacharier, Leonard B","Kattan, Meyer","O'Connor, George T","Wood, Robert A","Visness, Cynthia M","Durham, Stephen R","Larson, David","Esnault, Stephane","Ober, Carole","Gergen, Peter J","Becker, Patrice","Togias, Alkis","Gern, James E","Altman, Mathew C"],"date":"2020-04-26T11:00:00Z","year":2020,"_id":"32333915","week":"202017|Apr 20 - Apr 26","doi":"10.1016/j.jaci.2020.04.009","keywords":["ace2 expression","covid-19","sars-cov-2","allergic sensitization","asthma","receptor","respiratory allergy"],"source":"PubMed","topics":["Treatment","Mechanism"],"weight":1,"_version_":1665071049662791680,"score":8.518259,"similar":[{"pmid":32275855,"pmcid":"PMC7144619","title":"Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2.","text":["Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2.","The recent emergence of a novel coronavirus (SARS-CoV-2) in China has caused significant public health concerns. Recently, ACE2 was reported as an entry receptor for SARS-CoV-2. In this study, we present the crystal structure of the C-terminal domain of SARS-CoV-2 (SARS-CoV-2-CTD) spike (S) protein in complex with human ACE2 (hACE2), which reveals a hACE2-binding mode similar overall to that observed for SARS-CoV. However, atomic details at the binding interface demonstrate that key residue substitutions in SARS-CoV-2-CTD slightly strengthen the interaction and lead to higher affinity for receptor binding than SARS-RBD. Additionally, a panel of murine monoclonal antibodies (mAbs) and polyclonal antibodies (pAbs) against SARS-CoV-S1/receptor-binding domain (RBD) were unable to interact with the SARS-CoV-2 S protein, indicating notable differences in antigenicity between SARS-CoV and SARS-CoV-2. These findings shed light on the viral pathogenesis and provide important structural information regarding development of therapeutic countermeasures against the emerging virus.","Cell","Wang, Qihui","Zhang, Yanfang","Wu, Lili","Niu, Sheng","Song, Chunli","Zhang, Zengyuan","Lu, Guangwen","Qiao, Chengpeng","Hu, Yu","Yuen, Kwok-Yung","Wang, Qisheng","Zhou, Huan","Yan, Jinghua","Qi, Jianxun","32275855"],"abstract":["The recent emergence of a novel coronavirus (SARS-CoV-2) in China has caused significant public health concerns. Recently, ACE2 was reported as an entry receptor for SARS-CoV-2. In this study, we present the crystal structure of the C-terminal domain of SARS-CoV-2 (SARS-CoV-2-CTD) spike (S) protein in complex with human ACE2 (hACE2), which reveals a hACE2-binding mode similar overall to that observed for SARS-CoV. However, atomic details at the binding interface demonstrate that key residue substitutions in SARS-CoV-2-CTD slightly strengthen the interaction and lead to higher affinity for receptor binding than SARS-RBD. Additionally, a panel of murine monoclonal antibodies (mAbs) and polyclonal antibodies (pAbs) against SARS-CoV-S1/receptor-binding domain (RBD) were unable to interact with the SARS-CoV-2 S protein, indicating notable differences in antigenicity between SARS-CoV and SARS-CoV-2. These findings shed light on the viral pathogenesis and provide important structural information regarding development of therapeutic countermeasures against the emerging virus."],"journal":"Cell","authors":["Wang, Qihui","Zhang, Yanfang","Wu, Lili","Niu, Sheng","Song, Chunli","Zhang, Zengyuan","Lu, Guangwen","Qiao, Chengpeng","Hu, Yu","Yuen, Kwok-Yung","Wang, Qisheng","Zhou, Huan","Yan, Jinghua","Qi, Jianxun"],"date":"2020-04-11T11:00:00Z","year":2020,"_id":"32275855","week":"202015|Apr 06 - Apr 12","doi":"10.1016/j.cell.2020.03.045","keywords":["ace2","ctd","sars-cov-2","crystal structure","immunogenicity","receptor","receptor binding domain"],"source":"PubMed","topics":["Mechanism","Treatment"],"weight":1,"locations":["China"],"countries":["China"],"countries_codes":["CHN|China"],"_version_":1664637190193283072,"score":126.915665},{"pmid":32303424,"pmcid":"PMC7152872","title":"Assessing ACE2 expression patterns in lung tissues in the pathogenesis of COVID-19.","text":["Assessing ACE2 expression patterns in lung tissues in the pathogenesis of COVID-19.","It has been reported that SARS-CoV-2 may use ACE2 as a receptor to gain entry into human cells, in a way similar to that of SARS-CoV. Analyzing the distribution and expression level of ACE2 may therefore help reveal underlying mechanisms of viral susceptibility and post-infection modulation. In this study, we utilized previously uploaded information on ACE2 expression in various conditions including SARS-CoA to evaluate the role of ACE2 in SARS-CoV and extrapolate that to COVID-19. We found that the expression of ACE2 in healthy populations and patients with underlying diseases was not significantly different. However, based on the elevated expression of ACE2 in cigarette smokers, we speculate that long-term smoking may be a risk factor for COVID-19. Analysis of ACE2 in SARS-CoV infected cells suggests that ACE2 is not only a receptor but is also involved in post-infection regulation, including immune response, cytokine secretion, and viral genome replication. Moreover, we constructed Protein-protein interaction (PPI) networks and identified hub genes in viral activity and cytokine secretion. Our findings may help clinicians and researchers gain more insight into the pathogenesis of SARS-CoV-2 and design therapeutic strategies for COVID-19.","J Autoimmun","Li, Guoping","He, Xiang","Zhang, Lei","Ran, Qin","Wang, Junyi","Xiong, Anying","Wu, Dehong","Chen, Feng","Sun, Jinlyu","Chang, Christopher","32303424"],"abstract":["It has been reported that SARS-CoV-2 may use ACE2 as a receptor to gain entry into human cells, in a way similar to that of SARS-CoV. Analyzing the distribution and expression level of ACE2 may therefore help reveal underlying mechanisms of viral susceptibility and post-infection modulation. In this study, we utilized previously uploaded information on ACE2 expression in various conditions including SARS-CoA to evaluate the role of ACE2 in SARS-CoV and extrapolate that to COVID-19. We found that the expression of ACE2 in healthy populations and patients with underlying diseases was not significantly different. However, based on the elevated expression of ACE2 in cigarette smokers, we speculate that long-term smoking may be a risk factor for COVID-19. Analysis of ACE2 in SARS-CoV infected cells suggests that ACE2 is not only a receptor but is also involved in post-infection regulation, including immune response, cytokine secretion, and viral genome replication. Moreover, we constructed Protein-protein interaction (PPI) networks and identified hub genes in viral activity and cytokine secretion. Our findings may help clinicians and researchers gain more insight into the pathogenesis of SARS-CoV-2 and design therapeutic strategies for COVID-19."],"journal":"J Autoimmun","authors":["Li, Guoping","He, Xiang","Zhang, Lei","Ran, Qin","Wang, Junyi","Xiong, Anying","Wu, Dehong","Chen, Feng","Sun, Jinlyu","Chang, Christopher"],"date":"2020-04-19T11:00:00Z","year":2020,"_id":"32303424","week":"202016|Apr 13 - Apr 19","doi":"10.1016/j.jaut.2020.102463","keywords":["2019-ncov","ace2","covid-19","immune response","protein-protein interactions","sars-cov-2","susceptibility"],"source":"PubMed","topics":["Treatment","Mechanism"],"weight":1,"_version_":1664632934576947200,"score":125.51997},{"pmid":32319129,"title":"Managing childhood allergies and immunodeficiencies during respiratory virus epidemics - the 2020 COVID-19 pandemic.","text":["Managing childhood allergies and immunodeficiencies during respiratory virus epidemics - the 2020 COVID-19 pandemic.","While the world is facing an unprecedented pandemic with COVID-19, patients with chronic diseases need special attention and if warranted adaptation of their regular treatment plan. In children, allergy and asthma are among the most prevalent non-communicable chronic diseases, and health care providers taking care of these patients need guidance. At the current stage of knowledge, children have less severe symptoms of COVID-19, and severe asthma and immunodeficiency are classified as risk factors. In addition, there is no evidence that currently available asthma and allergy treatments, including antihistamines, corticosteroids, bronchodilators increase the risk of severe disease from COVID-19. Most countries affected by COVID-19 have opted for nationwide confinement, which means that communication with the primary clinician is often performed by telemedicine. Optimal disease control of allergic, asthmatic and immunodeficient children should be sought according to usual treatment guidelines. This statement of the EAACI Section on Pediatrics puts forward six recommendations for the management of childhood allergies and immunodeficiencies based on six underlying facts and existing evidence.","Pediatr Allergy Immunol","Brough, Helen A","Kalayci, Omer","Sediva, Anna","Untersmayr, Eva","Munblit, Daniel","Rodriquez Del Rio, Pablo","Vazquez-Ortiz, Marta","Arasi, Stefania","Alvaro-Lozano, Montserrat","Tsabouri, Sophia","Galli, Elena","Beken, Burcin","Eigenmann, Philippe A","32319129"],"abstract":["While the world is facing an unprecedented pandemic with COVID-19, patients with chronic diseases need special attention and if warranted adaptation of their regular treatment plan. In children, allergy and asthma are among the most prevalent non-communicable chronic diseases, and health care providers taking care of these patients need guidance. At the current stage of knowledge, children have less severe symptoms of COVID-19, and severe asthma and immunodeficiency are classified as risk factors. In addition, there is no evidence that currently available asthma and allergy treatments, including antihistamines, corticosteroids, bronchodilators increase the risk of severe disease from COVID-19. Most countries affected by COVID-19 have opted for nationwide confinement, which means that communication with the primary clinician is often performed by telemedicine. Optimal disease control of allergic, asthmatic and immunodeficient children should be sought according to usual treatment guidelines. This statement of the EAACI Section on Pediatrics puts forward six recommendations for the management of childhood allergies and immunodeficiencies based on six underlying facts and existing evidence."],"journal":"Pediatr Allergy Immunol","authors":["Brough, Helen A","Kalayci, Omer","Sediva, Anna","Untersmayr, Eva","Munblit, Daniel","Rodriquez Del Rio, Pablo","Vazquez-Ortiz, Marta","Arasi, Stefania","Alvaro-Lozano, Montserrat","Tsabouri, Sophia","Galli, Elena","Beken, Burcin","Eigenmann, Philippe A"],"date":"2020-04-23T11:00:00Z","year":2020,"_id":"32319129","week":"202017|Apr 20 - Apr 26","doi":"10.1111/pai.13262","keywords":["covid-19","sars-cov-2","allergy","asthma","biologics","children","coronavirus","corticosteroids","immunodeficiency","treatment"],"source":"PubMed","topics":["Prevention"],"weight":1,"locations":["Optimal"],"_version_":1664815087837249536,"score":120.48972},{"pmid":32224232,"title":"COVID-19: Pandemic Contingency Planning for the Allergy and Immunology Clinic.","text":["COVID-19: Pandemic Contingency Planning for the Allergy and Immunology Clinic.","In the event of a global infectious pandemic, drastic measures may be needed that limit or require adjustment of ambulatory allergy services. However, no rationale for how to prioritize service shut down and patient care exists. A consensus-based ad-hoc expert panel of allergy/immunology specialists from the United States and Canada developed a service and patient prioritization schematic to temporarily triage allergy/immunology services. Recommendations and feedback were developed iteratively, using an adapted modified Delphi methodology to achieve consensus. During the ongoing pandemic while social distancing is being encouraged, most allergy/immunology care could be postponed/delayed or handled through virtual care. With the exception of many patients with primary immunodeficiency, patients on venom immunotherapy, and patients with asthma of a certain severity, there is limited need for face-to-face visits under such conditions. These suggestions are intended to help provide a logical approach to quickly adjust service to mitigate risk to both medical staff and patients. Importantly, individual community circumstances may be unique and require contextual consideration. The decision to enact any of these measures rests with the judgment of each clinician and individual health care system. Pandemics are unanticipated, and enforced social distancing/quarantining is highly unusual. This expert panel consensus document offers a prioritization rational to help guide decision making when such situations arise and an allergist/immunologist is forced to reduce services or makes the decision on his or her own to do so.","J Allergy Clin Immunol Pract","Shaker, Marcus S","Oppenheimer, John","Grayson, Mitchell","Stukus, David","Hartog, Nicholas","Hsieh, Elena W Y","Rider, Nicholas","Dutmer, Cullen M","Vander Leek, Timothy K","Kim, Harold","Chan, Edmond S","Mack, Doug","Ellis, Anne K","Lang, David","Lieberman, Jay","Fleischer, David","Golden, David B K","Wallace, Dana","Portnoy, Jay","Mosnaim, Giselle","Greenhawt, Matthew","32224232"],"abstract":["In the event of a global infectious pandemic, drastic measures may be needed that limit or require adjustment of ambulatory allergy services. However, no rationale for how to prioritize service shut down and patient care exists. A consensus-based ad-hoc expert panel of allergy/immunology specialists from the United States and Canada developed a service and patient prioritization schematic to temporarily triage allergy/immunology services. Recommendations and feedback were developed iteratively, using an adapted modified Delphi methodology to achieve consensus. During the ongoing pandemic while social distancing is being encouraged, most allergy/immunology care could be postponed/delayed or handled through virtual care. With the exception of many patients with primary immunodeficiency, patients on venom immunotherapy, and patients with asthma of a certain severity, there is limited need for face-to-face visits under such conditions. These suggestions are intended to help provide a logical approach to quickly adjust service to mitigate risk to both medical staff and patients. Importantly, individual community circumstances may be unique and require contextual consideration. The decision to enact any of these measures rests with the judgment of each clinician and individual health care system. Pandemics are unanticipated, and enforced social distancing/quarantining is highly unusual. This expert panel consensus document offers a prioritization rational to help guide decision making when such situations arise and an allergist/immunologist is forced to reduce services or makes the decision on his or her own to do so."],"journal":"J Allergy Clin Immunol Pract","authors":["Shaker, Marcus S","Oppenheimer, John","Grayson, Mitchell","Stukus, David","Hartog, Nicholas","Hsieh, Elena W Y","Rider, Nicholas","Dutmer, Cullen M","Vander Leek, Timothy K","Kim, Harold","Chan, Edmond S","Mack, Doug","Ellis, Anne K","Lang, David","Lieberman, Jay","Fleischer, David","Golden, David B K","Wallace, Dana","Portnoy, Jay","Mosnaim, Giselle","Greenhawt, Matthew"],"date":"2020-04-01T11:00:00Z","year":2020,"_id":"32224232","week":"202014|Mar 30 - Apr 05","doi":"10.1016/j.jaip.2020.03.012","keywords":["allergic rhinitis","allergy","allergy immunotherapy","angioedema","asthma","atopic dermatitis","covid-19","food allergy","primary immunodeficiency","sars-cov-2","urticaria","venom allergy"],"source":"PubMed","topics":["Prevention"],"weight":1,"locations":["United States","Canada"],"countries":["Canada","United States"],"countries_codes":["CAN|Canada","USA|United States"],"_version_":1664640912819486720,"score":116.80384},{"pmid":32302706,"title":"Physiological and pathological regulation of ACE2, the SARS-CoV-2 receptor.","text":["Physiological and pathological regulation of ACE2, the SARS-CoV-2 receptor.","The renin-angiotensin system (RAS) is crucial for the physiology and pathology of all the organs. Angiotensin-converting enzyme 2 (ACE2) maintains the homeostasis of RAS as a negative regulator. Recently, ACE2 was identified as the receptor of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the coronavirus that is causing the pandemic of Coronavirus disease 2019 (COVID-19). Since SARS-CoV-2 must bind with ACE2 before entering the host cells in humans, the distribution and expression of ACE2 may be critical for the target organ of the SARS-CoV-2 infection. Moreover, accumulating evidence has demonstrated the implication of ACE2 in the pathological progression in tissue injury and several chronic diseases, ACE2 may also be essential in the progression and clinical outcomes of COVID-19. Therefore, we summarized the expression and activity of ACE2 in various physiological and pathological conditions, and discussed its potential implication in the susceptibility of SARS-CoV-2 infection and the progression and prognosis of COVID-19 patients in the current review.","Pharmacol Res","Li, Yanwei","Zhou, Wei","Yang, Li","You, Ran","32302706"],"abstract":["The renin-angiotensin system (RAS) is crucial for the physiology and pathology of all the organs. Angiotensin-converting enzyme 2 (ACE2) maintains the homeostasis of RAS as a negative regulator. Recently, ACE2 was identified as the receptor of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the coronavirus that is causing the pandemic of Coronavirus disease 2019 (COVID-19). Since SARS-CoV-2 must bind with ACE2 before entering the host cells in humans, the distribution and expression of ACE2 may be critical for the target organ of the SARS-CoV-2 infection. Moreover, accumulating evidence has demonstrated the implication of ACE2 in the pathological progression in tissue injury and several chronic diseases, ACE2 may also be essential in the progression and clinical outcomes of COVID-19. Therefore, we summarized the expression and activity of ACE2 in various physiological and pathological conditions, and discussed its potential implication in the susceptibility of SARS-CoV-2 infection and the progression and prognosis of COVID-19 patients in the current review."],"journal":"Pharmacol Res","authors":["Li, Yanwei","Zhou, Wei","Yang, Li","You, Ran"],"date":"2020-04-18T11:00:00Z","year":2020,"_id":"32302706","week":"202016|Apr 13 - Apr 19","doi":"10.1016/j.phrs.2020.104833","keywords":["angiotensin-converting enzyme 2","coronavirus disease 2019","diminazene aceturate (pubchem cid: 5284544)","resorcinolnaphthalein (pubchem cid: 337218)","severe acute respiratory syndrome coronavirus 2","xanthenone (pubchem cid: 7020)"],"source":"PubMed","topics":["Treatment","Mechanism"],"weight":1,"_version_":1664635401188409344,"score":113.95017}]}